Medtronic PLC (NYSE:MDT) – Equities research analysts at William Blair decreased their FY2019 EPS estimates for Medtronic in a research note issued on Tuesday, February 12th. William Blair analyst M. Kaczor now anticipates that the medical technology company will post earnings of $5.12 per share for the year, down from their previous forecast of $5.13. William Blair also issued estimates for Medtronic’s Q1 2020 earnings at $1.21 EPS and Q2 2020 earnings at $1.27 EPS.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 20th. The medical technology company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.07. Medtronic had a net margin of 7.44% and a return on equity of 13.51%. The business had revenue of $7.48 billion for the quarter, compared to the consensus estimate of $7.35 billion. During the same quarter in the previous year, the firm earned $1.07 earnings per share. The company’s revenue for the quarter was up 6.1% on a year-over-year basis.

Other equities analysts also recently issued research reports about the stock. Deutsche Bank initiated coverage on shares of Medtronic in a report on Wednesday, January 2nd. They set a “buy” rating and a $99.00 price target on the stock. Zacks Investment Research raised shares of Medtronic from a “hold” rating to a “buy” rating and set a $105.00 price target on the stock in a report on Tuesday, October 23rd. UBS Group initiated coverage on shares of Medtronic in a report on Wednesday, November 28th. They set a “buy” rating and a $112.00 price target on the stock. Oppenheimer reaffirmed a “buy” rating and set a $104.00 price target on shares of Medtronic in a report on Tuesday, November 20th. Finally, BTIG Research raised shares of Medtronic from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Tuesday, January 15th. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $104.09.

Shares of NYSE:MDT opened at $91.23 on Friday. The company has a current ratio of 2.56, a quick ratio of 2.11 and a debt-to-equity ratio of 0.48. Medtronic has a 1-year low of $76.41 and a 1-year high of $100.15. The company has a market cap of $122.53 billion, a price-to-earnings ratio of 19.13, a PEG ratio of 2.41 and a beta of 0.82.

The business also recently announced a quarterly dividend, which was paid on Friday, January 18th. Stockholders of record on Friday, December 28th were issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.19%. The ex-dividend date was Thursday, December 27th. Medtronic’s dividend payout ratio (DPR) is presently 41.93%.

In related news, CEO Omar Ishrak bought 12,000 shares of the stock in a transaction dated Wednesday, January 9th. The shares were purchased at an average price of $84.05 per share, with a total value of $1,008,600.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Karen L. Parkhill purchased 3,000 shares of Medtronic stock in a transaction that occurred on Wednesday, January 9th. The stock was acquired at an average price of $83.87 per share, for a total transaction of $251,610.00. The disclosure for this purchase can be found here. 0.28% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Tributary Capital Management LLC bought a new stake in Medtronic in the fourth quarter worth $27,000. Highwater Wealth Management LLC bought a new stake in Medtronic in the fourth quarter worth $39,000. IMS Capital Management bought a new stake in Medtronic in the third quarter worth $41,000. Contravisory Investment Management Inc. increased its position in Medtronic by 220.0% in the fourth quarter. Contravisory Investment Management Inc. now owns 480 shares of the medical technology company’s stock worth $44,000 after purchasing an additional 330 shares during the last quarter. Finally, Karp Capital Management Corp bought a new stake in Medtronic in the fourth quarter worth $46,000. Institutional investors own 81.62% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Recommended Story: Google Finance

Earnings History and Estimates for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.